Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
641 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05267106 | Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations(FIGHT-209) | terminated | Phase 2 | 83 | Incyte CorporationINDUSTRY | 9 | Dec 30, 2025 | clinicaltrials |
| NCT05898854 | [68Ga]Ga-FAPI PET/CT in Gastric and Gastroesophageal Junctional Cancer | completed | Phase 2 | 20 | Aalborg University HospitalOTHER | 1 | Dec 30, 2025 |
| clinicaltrials |
| NCT02854436 | An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies(Galahad) | completed | Phase 2 | 289 | Janssen Research & Development, LLCINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT02985957 | A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)(CheckMate 650) | completed | Phase 2 | 351 | Bristol-Myers SquibbINDUSTRY | 10 | Dec 22, 2025 | clinicaltrials |
| NCT07297914 | Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL(FORUM2) | not yet recruiting | Phase 2 / Phase 3 | 1,000 | Bambino Gesù Hospital and Research InstituteOTHER | 9 | Dec 22, 2025 | clinicaltrials |
| NCT02001272 | EWOC-1 Trial: Carboplatin +/- Paclitaxel in Vulnerable Elderly Patients With Stage III-IV Advanced Ovarian Cancer(EWOC-1) | completed | Phase 2 | 120 | Hospices Civils de LyonOTHER | 6 | Dec 19, 2025 | clinicaltrials |
| NCT04811027 | Combination Study With Eftilagimod Alpha (a Soluble LAG-3 Fusion Protein) and Pembrolizumab in Patients With Recurrent or Metastatic HNSCC(TACTI-003) | completed | Phase 2 | 171 | Immutep S.A.S.INDUSTRY | 9 | Dec 11, 2025 | clinicaltrials |
| NCT03725605 | LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) | completed | Phase 2 | 6 | Lytix Biopharma ASINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT02066220 | International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma | active not recruiting | Phase 2 / Phase 3 | 360 | Universitätsklinikum Hamburg-EppendorfOTHER | 16 | Dec 4, 2025 | clinicaltrials |
| NCT03498521 | A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site(CUPISCO) | completed | Phase 2 | 529 | Hoffmann-La RocheINDUSTRY | 33 | Nov 19, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) | terminated | Phase 2 | 111 | Incyte CorporationINDUSTRY | 11 | Nov 4, 2025 | clinicaltrials |
| NCT04497116 | Study of RP-3500, Camonsertib, in Advanced Solid Tumors(TRESR) | completed | Phase 1 / Phase 2 | 276 | Repare TherapeuticsINDUSTRY | 4 | Oct 21, 2025 | clinicaltrials |
| NCT07215182 | [68Ga]Ga-FAPI Total Body PET/CT for Better and Faster Imaging in Cancer(BEFAST) | recruiting | Phase 2 | 20 | Barbara Malene FischerOTHER | 1 | Oct 10, 2025 | clinicaltrials |
| NCT03731260 | (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis | active not recruiting | Phase 2 | 251 | Blueprint Medicines CorporationINDUSTRY | 13 | Sep 23, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT05658640 | HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies(HEM-iSMART D) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 15 | Sep 16, 2025 | clinicaltrials |
| NCT05745714 | HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART C) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT05751044 | HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies(HEM-iSMART B) | recruiting | Phase 1 / Phase 2 | 26 | Princess Maxima Center for Pediatric OncologyOTHER | 14 | Sep 16, 2025 | clinicaltrials |
| NCT03470922 | A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma(RELATIVITY-047) | active not recruiting | Phase 2 / Phase 3 | 714 | Bristol-Myers SquibbINDUSTRY | 25 | Sep 9, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT05222269 | [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients | terminated | Phase 2 | 1 | Pentixapharm AGINDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT04191616 | Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet(SELECT) | completed | Phase 2 | 54 | AmgenINDUSTRY | 8 | Sep 4, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT03322540 | Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05) | completed | Phase 2 | 154 | Incyte CorporationINDUSTRY | 18 | Aug 22, 2025 | clinicaltrials |
| NCT03597295 | A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202) | completed | Phase 2 | 94 | Incyte CorporationINDUSTRY | 9 | Aug 21, 2025 | clinicaltrials |
| NCT02872714 | A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) | completed | Phase 2 | 263 | Incyte CorporationINDUSTRY | 11 | Aug 14, 2025 | clinicaltrials |
| NCT03314181 | A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma | active not recruiting | Phase 2 | 156 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT04611126 | T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer | terminated | Phase 1 / Phase 2 | 6 | Inge Marie SvaneOTHER | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03314636 | Intensified Treatment With Carfilzomib in Myeloma Patients Still PET-positive After First Line Treatment.(CONPET) | active not recruiting | Phase 2 | 53 | Oslo University HospitalOTHER | 3 | Aug 8, 2025 | clinicaltrials |
| NCT05732389 | Immunotherapy in Patients With Early dMMR Rectal Cancer(RESET-R) | recruiting | Phase 2 | 39 | Odense University HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT03235245 | Immunotherapy With Ipilimumab and Nivolumab Preceded or Not by a Targeted Therapy With Encorafenib and Binimetinib(EBIN) | active not recruiting | Phase 2 | 271 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Aug 1, 2025 | clinicaltrials |
| NCT02730429 | Trial of Letrozole + Palbociclib/Placebo in Metastatic Endometrial Cancer | completed | Phase 2 | 78 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT03326791 | Aspirin in Colorectal Cancer Liver Metastases(ASAC) | active not recruiting | Phase 2 / Phase 3 | 466 | Oslo University HospitalOTHER | 3 | Jul 31, 2025 | clinicaltrials |
| NCT02730416 | Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer | completed | Phase 2 | 146 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 7 | Jul 29, 2025 | clinicaltrials |
| NCT03267589 | Trial in Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 25 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 3 | Jul 29, 2025 | clinicaltrials |
| NCT04341181 | ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling(ProTarget) | recruiting | Phase 2 | 300 | Ulrik LassenOTHER | 1 | Jul 25, 2025 | clinicaltrials |
| NCT03890952 | Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma | completed | Phase 2 | 40 | Ulrik LassenOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT03144674 | A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) | completed | Phase 2 | 110 | Incyte CorporationINDUSTRY | 12 | Jul 11, 2025 | clinicaltrials |
| NCT05123131 | Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma(Isa-RVD) | active not recruiting | Phase 2 | 54 | Cancer Trials IrelandNETWORK | 2 | Jul 8, 2025 | clinicaltrials |
| NCT06790082 | The Diagnostic Accuracy and Clinical Value of FAPI PET in Pleural Mesothelioma(FAPI-PM) | recruiting | Phase 2 | 70 | Aalborg University HospitalOTHER | 1 | Jul 3, 2025 | clinicaltrials |
| NCT04851717 | Investigation of Remimazolam in Children Undergoing Sedation for Medical Procedures | active not recruiting | Phase 2 / Phase 3 | 100 | Acacia Pharma LtdINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT02637687 | A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children(SCOUT) | active not recruiting | Phase 1 / Phase 2 | 154 | BayerINDUSTRY | 21 | Jun 22, 2025 | clinicaltrials |
| NCT03831776 | Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis(BosuPeg) | completed | Phase 2 | 212 | St. Olavs HospitalOTHER | 4 | Jun 8, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT06562348 | The ctDNA-RECIST Trial Part One(ctDNA-RECIST) | recruiting | Phase 2 | 167 | Karen-Lise Garm SpindlerOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy) | active not recruiting | Phase 2 | 250 | Partner Therapeutics, Inc.INDUSTRY | 18 | Apr 29, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials